DE60143755D1 - Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen - Google Patents

Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen

Info

Publication number
DE60143755D1
DE60143755D1 DE60143755T DE60143755T DE60143755D1 DE 60143755 D1 DE60143755 D1 DE 60143755D1 DE 60143755 T DE60143755 T DE 60143755T DE 60143755 T DE60143755 T DE 60143755T DE 60143755 D1 DE60143755 D1 DE 60143755D1
Authority
DE
Germany
Prior art keywords
dna vaccines
methods
expression
genemated
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60143755T
Other languages
English (en)
Inventor
David Hone
George Lewis
Timothy Fouts
Ken Bagley
Michael Boyson
Christine Obriecht
Mt Shata
Simon Agwale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Biotechnology Institute UMBI
Original Assignee
University of Maryland Biotechnology Institute UMBI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Biotechnology Institute UMBI filed Critical University of Maryland Biotechnology Institute UMBI
Application granted granted Critical
Publication of DE60143755D1 publication Critical patent/DE60143755D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
DE60143755T 2000-09-08 2001-09-10 Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen Expired - Lifetime DE60143755D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23140300P 2000-09-08 2000-09-08
US23137600P 2000-09-08 2000-09-08
US23107000P 2000-09-08 2000-09-08
US23144900P 2000-09-08 2000-09-08
PCT/US2001/028365 WO2002019968A2 (en) 2000-09-08 2001-09-10 Genetically engineered co-expression dna vaccines, construction methods and uses thereof

Publications (1)

Publication Number Publication Date
DE60143755D1 true DE60143755D1 (de) 2011-02-10

Family

ID=27499592

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60143755T Expired - Lifetime DE60143755D1 (de) 2000-09-08 2001-09-10 Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen

Country Status (6)

Country Link
US (1) US20020193330A1 (de)
EP (2) EP2329846B1 (de)
AT (1) ATE493495T1 (de)
AU (1) AU2001292610A1 (de)
DE (1) DE60143755D1 (de)
WO (1) WO2002019968A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20050244434A1 (en) * 1999-08-12 2005-11-03 Cohen David I Tat-based tolerogen compositions and methods of making and using same
AU2003243443B2 (en) * 2002-06-21 2008-11-06 Centocor, Inc. Method for generating monoclonal antibodies
WO2004085613A2 (en) * 2003-03-19 2004-10-07 Stratagene Electrocompetent host cells
EP1566439A1 (de) * 2004-02-20 2005-08-24 Nestec S.A. Prophylaxe oder Behandlung von Obesitas
US7927580B2 (en) * 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
WO2006078271A2 (en) * 2004-04-20 2006-07-27 The United States Of America As Represented By The Secretary Of The Navy Cloning and expression of the full length 110 kda antigen of orientia tsutsugamushi to be used as a vaccine component against scrub typhus
CN100572541C (zh) * 2007-05-28 2009-12-23 中国农业科学院兰州兽医研究所 口蹄疫病毒双效疫苗载体、其制备方法及应用
EP2152889B1 (de) 2007-05-29 2017-03-15 Nature Technology Corporation Vektoren und verfahren zur genetischen immunisierung
SG10201408165WA (en) * 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
US9023363B2 (en) * 2008-10-21 2015-05-05 International Vaccine Institute A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines
CA2755897C (en) 2009-03-23 2020-01-28 Nanirx, Inc. Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
WO2012000188A1 (en) * 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Recombinant tumor vaccine and method of producing such
AU2011333756B2 (en) * 2010-11-25 2017-06-15 Equaly S.A. Modulation of antigen immunogenicity by deleting epitopes recognized by NKT cells
JP2014501726A (ja) * 2010-11-25 2014-01-23 イムネイト・ソシエテ・ア・レスポンサビリテ・リミテ Ｎｋｔ細胞によって認識されるエピトープの添加による、抗原免疫原性の調節
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
MX2019004774A (es) * 2016-11-01 2019-08-05 Novo Nordisk As Vacuna de acido desoxirribonucleico (adn) tolerogenica.
US11419928B2 (en) 2017-10-25 2022-08-23 The Johns Hopkins University Methods and compositions for treating cancer
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5416017A (en) * 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters
IL101715A (en) * 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
EP0803573A1 (de) * 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronische Expressionskonstrukt mit Cytokinen für multivalente Impstoffe
US6589529B1 (en) * 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
CA2449663A1 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant

Also Published As

Publication number Publication date
US20020193330A1 (en) 2002-12-19
AU2001292610A1 (en) 2002-03-22
EP1315816A4 (de) 2006-05-17
EP1315816B1 (de) 2010-12-29
EP1315816A2 (de) 2003-06-04
EP2329846B1 (de) 2014-11-12
WO2002019968A3 (en) 2002-05-16
EP2329846A1 (de) 2011-06-08
ATE493495T1 (de) 2011-01-15
WO2002019968A9 (en) 2002-07-25
WO2002019968A2 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
DE60143755D1 (de) Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen
DK1951296T4 (da) Celleafledte viral vacciner med lave niveauer af restcelle-DNA
NZ593220A (en) Immunostimulatory oligonucleotides
ATE521621T1 (de) Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
WO2007024941A3 (en) Polyvalent vaccine
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
ATE276758T1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
ATE376591T1 (de) Neisseria meningitidis antigene und zusammenstellungen
ATE485056T1 (de) Verbesserte impfstoffe
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
EA200800837A1 (ru) Иммуностимулирующая одноцепочечная рибонуклеиновая кислота с фосфодиэфирным остовом
DK1796717T3 (da) Kombinationsvaccine
ATE529123T1 (de) Synthetische glykolipopeptide als impfstoffe
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
DK1740206T3 (da) PHEP, en aminosyrepermease af Staphylococcus Aureus
EP1667634A4 (de) Anthrax-vakzine
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE359815T1 (de) Streptococcus-phocae-vakzine
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
WO2004073604A3 (en) Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
BRPI0415742A (pt) vacina para a doença periodontal
ATE495757T1 (de) Attenuierte bakterielle lebendvakzine
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
TH87147B (th) วัคซีนสำหรับการทำให้เกิดภูมิคุ้มกันที่ต้านเชื้อเฮลิโคแมคเตอร์